文献速递糖尿病

口服葡萄糖耐量试验期间内源性葡萄糖生成高于等血糖静脉葡萄糖输注

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.
PubMed 文献 · J Clin Endocrinol Metab · 2016-08-17

本研究为单盲随机交叉试验,纳入10例2型糖尿病患者和10例匹配的非糖尿病对照者,比较75g口服葡萄糖耐量试验(OGTT)、等血糖静脉葡萄糖输注(IIGI)及IIGI联合胰高血糖素输注三种条件下葡萄糖动力学。结果显示两组在OGTT期间内源性葡萄糖生成(EGP)的抑制程度均低于IIGI,且外源性胰高血糖素输注未能使EGP恢复至OGTT时水平,基于本实验设计无法将差异归因于OGTT初期观察到的胰高血糖素抑制延迟。

要点

  • 两组在OGTT期间EGP抑制程度均低于IIGI期间。
  • IIGI期间联合胰高血糖素输注未能使EGP恢复至OGTT水平。
  • 对照组OGTT期间葡萄糖消失率高于IIGI,糖尿病组各天相似。

核心结论

  • 在2型糖尿病患者和非糖尿病对照者中,OGTT期间EGP的抑制程度均低于IIGI期间。
  • 基于本实验设计,无法将这一差异归因于OGTT初期观察到的胰高血糖素抑制延迟。

研究设计与样本

  • 单盲、随机、交叉研究,在专业研究单位进行。
  • 纳入10例2型糖尿病患者(年龄57.1±6.7岁,BMI 29.0±4.3 kg/m2,HbA1c 53.8±11.0 mmol/mol,糖尿病病程9.2±5.0年)和10例匹配的非糖尿病对照者(年龄56.0±10.7岁,BMI 29.8±2.9 kg/m2,HbA1c 33.8±5.5 mmol/mol)。
  • 三个实验日:75g口服葡萄糖耐量试验(OGTT)、等血糖静脉葡萄糖输注(IIGI)、以及IIGI联合胰高血糖素输注(0至25分钟静脉输注胰高血糖素0.8 ng/kg/min,设计用于模拟2型糖尿病组OGTT期间门静脉胰高血糖素浓度)。
  • 采用示踪剂方法评估葡萄糖动力学。

主要发现

  • 对照组OGTT期间葡萄糖消失率高于IIGI期间,而糖尿病组各实验日相似。
  • 两组在IIGI期间EGP的抑制程度均高于OGTT期间。
  • IIGI期间外源性胰高血糖素输注未能使EGP恢复至OGTT期间观察到的水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基于本实验设计,无法将OGTT与IIGI期间EGP抑制程度的差异归因于OGTT初期观察到的胰高血糖素抑制延迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Oral glucose ingestion elicits a larger insulin response and delayed suppression of glucagon compared to isoglycemic IV glucose infusion (IIGI). OBJECTIVE: We studied whether these differences translate into effects on endogenous glucose production (EGP) and glucose disposal in patients with type 2 diabetes and nondiabetic control subjects. DESIGN: This was a single-blinded, randomized, crossover study. SETTING: The study was conducted at a specialized research unit. PARTICIPANTS: Ten patients with type 2 diabetes (age, [mean ± SD] 57.1 ± 6.7 years; body mass index, 29.0 ± 4.3 kg/m2; hemoglobin A1c, 53.8 ± 11.0 mmol/mol; duration of diabetes, 9.2 ± 5.0 years) and 10 matched nondiabetic control subjects (age, 56.0±10.7 years; body mass index, 29.8 ± 2.9 kg/m2; hemoglobin A1c, 33.8 ± 5.5 mmol/mol) participated. INTERVENTIONS: Three experimental days: 75 g-oral glucose tolerance test (OGTT), IIGI, and IIGI+glucagon (IIGI with a concomitant IV glucagon infusion [0.8 ng/kg/min from 0 to 25 minutes] designed to mimic portal glucagon concentrations during OGTT in the type 2 diabetic group) were undertaken. MAIN OUTCOME MEASURES: Glucose kinetics were assessed by tracer methodology. RESULTS: Glucose rate of disappearance was higher during the OGTT vs IIGI in the control group, but similar on all days in the diabetic group. Surprisingly, in both groups, EGP was more suppressed during IIGI than during OGTT, and exogenous glucagon infusion during IIGI did not restore EGP to the levels observed during OGTT. CONCLUSION: EGP was less suppressed during OGTT than during IIGI in both patients with type 2 diabetes and in nondiabetic control subjects. Based on the present experimental design, it was not possible to attribute this difference to the delayed glucagon suppression observed in the initial phase of the OGTT.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lund A, Bagger JI, Christensen M, et al. Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. J Clin Endocrinol Metab. 2016. PMID: 27533305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。